The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Prevalence and Risk Factors for Aminoglycoside Nephrotoxicity in Intensive Care Units
Open accessAbstract
In order to assess the prevalence of and risk factors for aminoglycoside-associated nephrotoxicity in intensive care units (ICUs), we evaluated 360 consecutive patients starting aminoglycoside therapy in an ICU. The patients had a baseline calculated glomerular filtration rate (cGFR) of ≥30 ml/min/1.73 m 2. Among these patients, 209 (58%) developed aminoglycoside-associated nephrotoxicity (the acute kidney injury [AKI] group, which consisted of individuals with a decrease in cGFR of >20% from the baseline cGFR), while 151 did not (non-AKI group). Both groups had similar baseline cGFRs. The AKI group developed a lower cGFR nadir (45 ± 27 versus 79 ± 39 ml/min/1.73 m 2 for the non-AKI group;P< 0.001); was older (56 ± 18 years versus 52 ± 19 years for the non-AKI group;P= 0.033); had a higher prevalence of diabetes (19.6% versus 9.3% for the non-AKI group;P= 0.007); was more frequently treated with other nephrotoxic drugs (51% versus 38% for the non-AKI group;P= 0.024); used iodinated contrast more frequently (18% versus 8% for the non-AKI group;P= 0.0054); and showed a higher prevalence of hypotension (63% versus 44% for the non-AKI group;P= 0.0003), shock (56% versus 31% for the non-AKI group;P< 0.0001), and jaundice (19% versus 8% for the non-AKI group;P= 0.0036). The mortality rate was 44.5% for the AKI group and 29.1% for the non-AKI group (P= 0.0031). A logistic regression model identified as significant (P< 0.05) the following independent factors that affected aminoglycoside-associated nephrotoxicity: a baseline cGFR of <60 ml/min/1.73 m 2(odds ratio [OR], 0.42), diabetes (OR, 2.13), treatment with other nephrotoxins (OR, 1.61) or iodinated contrast (OR, 2.13), and hypotension (OR, 1.83). In conclusion, AKI was frequent among ICU patients receiving an aminoglycoside, and it was associated with a high rate of mortality. The presence of diabetes or hypotension and the use of other nephrotoxic drugs and iodinated contrast were independent risk factors for the development of aminoglycoside-associated nephrotoxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
Targeting the KEAP1-NRF2 system to prevent kidney disease progression
Nezu, M., Suzuki, N., & Yamamoto, M. (2017) · American Journal of Nephrology · doi:10.1159/000475890 · Cited by 3,447
Cited by
Aminoglycoside modifying enzymes
Ramirez, M. S., & Tolmasky, M. E. (2010) · Drug Resistance Updates · doi:10.1016/j.drup.2010.08.003 · Cited by 1,464
Metadata
- Authors
- Oliveira, J. F. P., Silva, C. A., Barbieri, C. D., Oliveira, G. M., Zanetta, D. M. T., & Burdmann, E. A.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2009-07
- Volume
- 53
- Issue
- 7
- Pages
- 2887-2891
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2158889234
- Cited by
- 181
- References
- 2
- FWCI
- 4.95
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prevalence and Risk Factors for Aminoglycoside Nephrotoxicity in Intensive Care Units. https://app.cochat.ai/papers/10.1128/aac.01430-08
- The paper
- Oliveira, J. F. P., Silva, C. A., Barbieri, C. D., Oliveira, G. M., Zanetta, D. M. T., & Burdmann, E. A. (2009). Prevalence and Risk Factors for Aminoglycoside Nephrotoxicity in Intensive Care Units. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01430-08
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.